NO20091830L - Spiro-piperidinderivater som VIa reseptorantagonister - Google Patents

Spiro-piperidinderivater som VIa reseptorantagonister

Info

Publication number
NO20091830L
NO20091830L NO20091830A NO20091830A NO20091830L NO 20091830 L NO20091830 L NO 20091830L NO 20091830 A NO20091830 A NO 20091830A NO 20091830 A NO20091830 A NO 20091830A NO 20091830 L NO20091830 L NO 20091830L
Authority
NO
Norway
Prior art keywords
spiro
receptor antagonists
piperidine derivatives
via receptor
present
Prior art date
Application number
NO20091830A
Other languages
English (en)
Norwegian (no)
Inventor
Patrick Schnider
Hasane Ratni
Caterina Bissantz
Christophe Grundschober
Mark Rogers-Evans
Rafaello Masciadri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20091830L publication Critical patent/NO20091830L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20091830A 2006-12-07 2009-05-11 Spiro-piperidinderivater som VIa reseptorantagonister NO20091830L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125634 2006-12-07
PCT/EP2007/062985 WO2008068185A1 (fr) 2006-12-07 2007-11-29 Dérivés de spiro-pipéridine

Publications (1)

Publication Number Publication Date
NO20091830L true NO20091830L (no) 2009-07-06

Family

ID=39295880

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091830A NO20091830L (no) 2006-12-07 2009-05-11 Spiro-piperidinderivater som VIa reseptorantagonister

Country Status (21)

Country Link
US (3) US20080139554A1 (fr)
EP (1) EP2102207B1 (fr)
JP (1) JP2010511661A (fr)
KR (1) KR101050568B1 (fr)
CN (1) CN101547923A (fr)
AR (1) AR064135A1 (fr)
AT (1) ATE469900T1 (fr)
AU (1) AU2007328995B2 (fr)
BR (1) BRPI0720004A2 (fr)
CA (1) CA2670674A1 (fr)
CL (1) CL2007003482A1 (fr)
DE (1) DE602007006990D1 (fr)
ES (1) ES2344131T3 (fr)
IL (1) IL198544A (fr)
MX (1) MX2009005504A (fr)
NO (1) NO20091830L (fr)
PE (1) PE20081252A1 (fr)
RU (1) RU2009119394A (fr)
TW (1) TW200838518A (fr)
WO (1) WO2008068185A1 (fr)
ZA (1) ZA200903496B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2009123133A (ru) 2006-12-22 2011-01-27 Ф.Хоффманн-Ля Рош Аг (Ch) Производные спиро-пиперидина
ES2447590T3 (es) 2008-04-29 2014-03-12 Novartis Ag Derivados de espiro-indol para el tratamiento de enfermedades parasitarias
MX2017006294A (es) * 2014-11-14 2017-08-21 Hoffmann La Roche Espiro-tiazolonas.
WO2017137334A1 (fr) * 2016-02-08 2017-08-17 F. Hoffmann-La Roche Ag Spiroindolinones utilisés en tant qu'inhibiteurs de ddr1
ES2951874T3 (es) * 2017-09-05 2023-10-25 Neumora Therapeutics Inc Antagonistas del receptor de vasopresina y productos y métodos relacionados con los mismos

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3370091A (en) 1964-06-15 1968-02-20 Hoffmann La Roche 2 aminobenzhydrylhalides
US3531467A (en) 1966-12-23 1970-09-29 Hoffmann La Roche Process for the preparation of 2,3,4,5-tetrahydro - 5 - aryl - 1h - 1,4 - benzodiazepine derivatives
US4209625A (en) 1977-04-21 1980-06-24 American Hoechst Corporation Spiro[indoline-3,4'-piperidine]s
DE3818830A1 (de) 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh Bicyclische carboxamide, verfahren zu ihrer herstellung, deren vorstufen, und diese verbindungen enthaltende arzneimittel
EP0450761A1 (fr) * 1990-03-02 1991-10-09 Merck & Co. Inc. Antagonistes d'oxytocine spirocycliques
DK78692D0 (da) 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
CA2143117A1 (fr) 1992-10-07 1994-04-14 Ben E. Evans Antagonistes du recepteur de l'oxytocine de la tocolyse
US5670509A (en) * 1993-09-27 1997-09-23 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
IT1271026B (it) 1994-10-21 1997-05-26 Isagro Ricerca Srl Derivati dell'acido b-amminopropionico ad attivita' fungicida
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
PL327146A1 (en) 1995-12-14 1998-11-23 Merck & Co Inc Antagonists of the gonadotrophin liberating hormone
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US6166209A (en) 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
CO5150201A1 (es) 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
GB0003397D0 (en) 2000-02-14 2000-04-05 Merck Sharp & Dohme Therapeutic agents
ATE255578T1 (de) 2000-05-12 2003-12-15 Solvay Pharm Bv Piperazin- und piperidinverbindungen
ATE266031T1 (de) 2000-09-29 2004-05-15 Lilly Co Eli Verfahren und verbindungen zur behandlung proliferativer erkrankungen
CA2467825A1 (fr) 2001-11-27 2003-06-05 F. Hoffmann-La Roche Ag Derives de benzothiazole
FR2833948B1 (fr) 2001-12-21 2004-02-06 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et leur utilisation en tant que medicament
US20040152741A1 (en) 2002-09-09 2004-08-05 Nps Allelix Corporation Arylglycine derivatives and their use as glycine transport inhibitors
AU2003263155A1 (en) 2002-09-20 2004-04-08 H. Lundbeck A/S Method for manufacture of dihydroisobenzofuran derivatives
MXPA05003948A (es) 2002-10-17 2005-06-17 Amgen Inc Derivados de bencimidazol y su uso como ligandos de receptor vaniloide.
WO2004069809A1 (fr) 2003-02-03 2004-08-19 Janssen Pharmaceutica N.V. Mercaptoimidazoles en tant qu'agonistes du recepteur ccr2
US7244852B2 (en) 2003-02-27 2007-07-17 Abbott Laboratories Process for preparing 2-methylpyrrolidine and specific enantiomers thereof
ATE467616T1 (de) * 2003-04-11 2010-05-15 High Point Pharmaceuticals Llc Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
CA2544602A1 (fr) 2003-11-04 2005-05-26 Elixir Pharmaceuticals, Inc. Composes therapeutiques et utilisations correspondantes
EP1701959A1 (fr) * 2003-12-22 2006-09-20 Pfizer Limited Dérivés de triazole comme antagonistes de vasopréssine
AU2004309419A1 (en) 2003-12-23 2005-07-14 Arena Pharmaceuticals, Inc. Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
GB0400700D0 (en) * 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
AU2005268893B2 (en) 2004-08-05 2011-10-13 F. Hoffmann-La Roche Ag Indole, indazole or indoline derivatives
US8138342B2 (en) 2004-10-12 2012-03-20 High Point Pharmacueticals, LLC 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds
JP4935356B2 (ja) * 2004-10-13 2012-05-23 ソニー株式会社 再生装置、撮像装置および画面表示方法
US20080234252A1 (en) 2005-05-18 2008-09-25 Pfizer Inc Compounds Useful in Therapy
US8190027B2 (en) 2006-07-12 2012-05-29 Tellabs Operations, Inc. Multifunctional and reconfigurable optical node and optical network
SI1904477T1 (sl) * 2005-07-14 2009-06-30 Hoffmann La Roche Derivati indol-3-karbonil-spiro-piperidina kot antagonisti V1A receptorja
WO2007028638A1 (fr) 2005-09-09 2007-03-15 Euro-Celtique S.A. Composes fondus et spirocycle ainsi que l'utilisation de ceux-ci
RU2009123133A (ru) 2006-12-22 2011-01-27 Ф.Хоффманн-Ля Рош Аг (Ch) Производные спиро-пиперидина
WO2008080844A1 (fr) 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Dérivés azaspiro
KR101129791B1 (ko) 2007-01-12 2012-03-23 에프. 호프만-라 로슈 아게 스파이로피페리딘 글리신아마이드 유도체

Also Published As

Publication number Publication date
CN101547923A (zh) 2009-09-30
KR20090079255A (ko) 2009-07-21
ZA200903496B (en) 2010-03-31
PE20081252A1 (es) 2008-09-04
EP2102207A1 (fr) 2009-09-23
IL198544A (en) 2012-06-28
JP2010511661A (ja) 2010-04-15
AU2007328995A1 (en) 2008-06-12
US20080139554A1 (en) 2008-06-12
IL198544A0 (en) 2010-02-17
US20080146568A1 (en) 2008-06-19
WO2008068185A1 (fr) 2008-06-12
ES2344131T3 (es) 2010-08-18
RU2009119394A (ru) 2011-01-20
KR101050568B1 (ko) 2011-07-19
AU2007328995B2 (en) 2012-04-26
TW200838518A (en) 2008-10-01
BRPI0720004A2 (pt) 2013-12-17
US8202993B2 (en) 2012-06-19
CL2007003482A1 (es) 2008-07-04
CA2670674A1 (fr) 2008-06-12
US20080139553A1 (en) 2008-06-12
EP2102207B1 (fr) 2010-06-02
MX2009005504A (es) 2009-06-03
DE602007006990D1 (de) 2010-07-15
AR064135A1 (es) 2009-03-18
ATE469900T1 (de) 2010-06-15

Similar Documents

Publication Publication Date Title
NO20092342L (no) Azaspiroderivativater
NO20091766L (no) Spiro-piperidinderivater
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
NO20073719L (no) Kjemiske forbindelser
NO20082709L (no) Kjemiske forbindelser
NO20073876L (no) Pyrazolopyrimidinderivater som mGluR2-antagonister
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20055688L (no) Organiske forbindelser
NO20085100L (no) Nye forbindelser
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20054414L (no) Dihydropteridinoner, metoder for deres fremstilling og bruk av disse som medisiner
NO20060324L (no) [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni
NO20090328L (no) Nye forbindelser 385
NO20091683L (no) Kjemiske forbindelser
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
NO20076195L (no) Nye 2-azetidinonderivater for behandling av hyperlipidemiske sykdommer
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
NO20092689L (no) Quinuclidinolderivater som muskarin reseptorantagonister
NO20092149L (no) Spiro-piperidinderivater
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application